clinoptilolite
Clinoptilolite is a natural zeolite composed of a microporous arrangement of silica and alumina tetrahedra. It has the complex formula (Na,K,Ca)2–3Al3(Al,Si)2Si13O36•12H2O. It forms as white, green to reddish tabular monoclinic tectosilicate crystals with a Mohs hardness of 3.5 to 4 and a specific gravity of 2.1 to 2.2. It commonly occurs as a devitrification product of volcanic glass shards in tuff and as vesicle fillings in basalts, andesites and rhyolites. It was described in 1969 from an occurrence in the Barstow Formation, San Bernardino County, California. Sodium levels in clinoptilolite are generally higher than potassium levels, as is the case with the San Bernardino Barstow Formation, but there are sources that are potassium-rich and have minimal sodium. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2008 (NCT00623675)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaClinoptilolite ↗
Also known as
- clinoptilolite
- clinoptilolite
- clinoptilolite
- clinoptilolite, dealuminated
- clinoptilolite (na(alsi5o12).xh2o)
- klinosorb
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03090542 | N/A | May 15, 2017 | Canadian Collaborative Research Network, Glock Health, Science and Research, Gmbh |
| NCT00623675 | Phase 4 | Feb 1, 2008 | CreoMed, Inc., Nema Research |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Collaborative Research Network | Academic/Hospital | 1 | 1 | 1 | 2017 |
| CreoMed, Inc. | For profit | 1 | 1 | 1 | 2008 |
| Glock Health, Science and Research, Gmbh | For profit | 1 | 0 | 1 | 2017 |
| Nema Research | For profit | 1 | 0 | 1 | 2008 |